Core Viewpoint - Japan's Eisai and Biogen will relocate part of the production capacity for Lecanemab to the United States [1] Group 1 - The decision to move production capacity indicates a strategic shift towards enhancing operational efficiency and meeting market demand in the U.S. [1]